Interestingly, FTY720, also known as fingolimod, a clinically approved drug to treat MS (Brinkmann et al., 2010) has been shown to be able to block the activity of TRPM7 (Qin et al., 2013). This evidence concerns the gene TRPM7 and myeloid sarcoma.